Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announces its partnership with the Susan G. Komen Race for the Cure® Houston event on Saturday, October 2, 2021.
September 28, 2021
· 6 min read